{ "schema_version": "uw.editorial_geo.v1", "representation_profile": "lossless_source_sections", "local_stage_only": true, "catalog_id": "DEP-06-N08", "article_index": "DEP-06-N08", "language": "en", "headline": "Gabapentinoids and other medicines with potential for problematic use", "description": "Gabapentinoids and other medicines with potential for problematic use", "short_answer": "The catch-all label “pharma” says little about a particular situation. Which medicine does someone take, why was it prescribed, what helped and what difficulties have appeared? Gabapentin and pregabalin can be part of useful medical care; questions about physical dependence, withdrawal and control also deserve attention. You can begin by contacting the prescriber and describing facts already known. There is no need first to declare all treatment a mistake or test yourself with an independent interruption.", "short_answer_source": { "kind": "opening_after_h1", "role": "lead", "start_utf16": 73, "end_utf16": 583, "sha256_utf8": "bec61928a2acc30db084e2e1b193d32c6afcb6828c0f2e67457990593eda87ac" }, "headline_source": { "role": "h1_heading", "start_utf16": 2, "end_utf16": 71, "sha256_utf8": "f0a5f0c931e5218128b70d845bc54d477cbefd90d32ae3edd5ae42e6c9332765" }, "entities": [], "questions": [ { "q": "A dangerous state matters more than an exact label", "a": "If someone is not responding normally, is difficult to wake or has slowed or difficult breathing, immediate medical help is needed; a life-threatening state requires a local emergency route. The FDA identifies these signs in its warning about gabapentin and pregabalin's breathing risks. Do not wait for a complete history or certainty about the cause. [FDA, breathing risks](https://www.fda.gov/safety/medical-product-safety-information/neurontin-gralise-horizant-gabapentin-and-lyrica-lyrica-cr-pregabalin-drug-safety-communication).\n\nWith suspected dangerous poisoning or seizures, do not delay assessment to establish whether “this is addiction.” Share known information and follow the emergency service's instructions; this article offers no home neutralisation or another substance to compensate for effects. [NHS, poisoning](https://www.nhs.uk/conditions/poisoning/).\n\nAn immediate threat of self-harm calls for urgent local help. If suicidal thoughts appear, contact a professional immediately; danger or an inability to keep yourself safe requires an emergency route. Notes and discussion of the medication plan can wait. [NIMH, Depression](https://www.nimh.nih.gov/health/publications/depression).", "source_spans": [ { "role": "h2_heading", "start_utf16": 588, "end_utf16": 638, "sha256_utf8": "3a21459de0c9ac36de4fca3832eaf7ceb7d508d41206fba9d70567f411eb4961" }, { "role": "h2_answer", "start_utf16": 640, "end_utf16": 1847, "sha256_utf8": "fcdad51bdb9e193749c1d27c07ac76a2fad78b3ed1f0c5ab2ad78ab1c62b6305" } ], "block_ids": [ "p0004", "p0005", "p0006" ], "source_segment_index": 1 }, { "q": "Consider the particular medicine and its purpose", "a": "Gabapentin and pregabalin are gabapentinoids, but their names cannot be replaced by one general label. The UK's NHS describes gabapentin for epilepsy and nerve pain, and pregabalin for epilepsy, anxiety and nerve pain. These are statements from particular patient materials, rather than an individual prescription or confirmation that indications have identical approval in every country. [NHS, gabapentin](https://www.nhs.uk/medicines/gabapentin/about-gabapentin/), [NHS, pregabalin](https://www.nhs.uk/medicines/pregabalin/about-pregabalin/).\n\nSomeone may have real pain, an illness or anxiety, and treatment may genuinely have helped. Relief and the ability to work matter. They do not automatically confirm safety, continued control or a measured improvement in thinking. Difficulties when treatment changes do not make earlier benefits imaginary either.\n\nThe prescribing goal and current circumstances matter to the conversation. If the name, history or instructions are unclear, say so. Help should not wait for perfect knowledge of every medicine. During a routine contact, you can ask a professional or pharmacist to help clarify details of the particular medicine; during danger, identifying its name must not delay help.", "source_spans": [ { "role": "h2_heading", "start_utf16": 1852, "end_utf16": 1900, "sha256_utf8": "50786d1d67f2f46ee24e961875258f58e8e4244ab18acceac8ea2d41de2fd29c" }, { "role": "h2_answer", "start_utf16": 1902, "end_utf16": 3132, "sha256_utf8": "ad70daa506bfb36d090018288136e29c8ce579eca36f50eee610e053fd0b2808" } ], "block_ids": [ "p0008", "p0009", "p0010" ], "source_segment_index": 2 }, { "q": "Adaptation, withdrawal and difficulties with control", "a": "In its communication of 8 January 2026, the MHRA describes physical dependence as the body becoming accustomed to a medicine, with withdrawal symptoms possible when it is stopped or reduced. Addiction also concerns a strong drive to take the medicine and difficulties controlling use. These concepts are related, but physical dependence does not necessarily mean addiction. [MHRA, information about risks](https://www.gov.uk/drug-safety-update/improving-information-supplied-with-gabapentinoids-pregabalin-slash-gabapentin-benzodiazepines-and-z-drugs).\n\nTolerance concerns a change in effect: someone may feel that earlier relief has gone and more is needed. This is a reason to describe the change to a professional, rather than increase use independently. One feeling cannot distinguish tolerance from a worsening of the treated condition or another cause. Symptoms after a change, a schedule and duration do not by themselves establish a substance use disorder diagnosis.\n\nWithdrawal and the return of an illness also need separate consideration. For example, the NHS warns that missed pregabalin doses during epilepsy treatment can trigger a seizure. An intentional interruption to prove “independence” can therefore create a new risk. This does not mean ignoring a serious adverse reaction: it requires timely medical assessment and a decision based on the person's condition.", "source_spans": [ { "role": "h2_heading", "start_utf16": 3137, "end_utf16": 3189, "sha256_utf8": "3aa9ad91ee4c3b794ceb2b2338a23064bc72d66b4b3b61916f4f81ffec99236b" }, { "role": "h2_answer", "start_utf16": 3191, "end_utf16": 4572, "sha256_utf8": "733f4f1fcee6b549186600c421e1b8d9c17a0caded9e6265d26b79ff34bc3beb" } ], "block_ids": [ "p0012", "p0013", "p0014" ], "source_segment_index": 3 }, { "q": "Why every medicine cannot be grouped together", "a": "The MHRA considers gabapentinoids alongside benzodiazepines and Z-drugs when discussing information about known risks. This does not turn the three classes or every prescription medicine into identical substances with one model of dependence. Another medicine needs its own indications, warnings and circumstances of use.\n\nThis MHRA review excludes specialist epilepsy use and sedation during procedures from its scope. That exclusion does not mean absence of risk or a requirement to stop necessary treatment. The agency also did not conduct a new assessment of effectiveness and doses for every prescription in this review. Information updates were being introduced in January 2026; the communication does not confirm completed changes on every package worldwide.\n\nLabels such as “from a pharmacy” or “natural” do not replace assessment of the particular product. Continuing useful treatment, reviewing a prescription and additional help can all be discussed. This article offers no universal substitute and does not call every long-term treatment addiction. Understanding current benefits, difficulties and the medical task matters more than choosing a general slogan about medicines.", "source_spans": [ { "role": "h2_heading", "start_utf16": 4577, "end_utf16": 4622, "sha256_utf8": "8aafe7e9ea36f6c3f6e2d2647c3e5c719f2c75e26d1637ec27448042e4c76a85" }, { "role": "h2_answer", "start_utf16": 4624, "end_utf16": 5811, "sha256_utf8": "63e3ec83786e0a466eaf2c36457aa1e07f9bafaa1a8ab97f64fa2646b9398847" } ], "block_ids": [ "p0016", "p0017", "p0018" ], "source_segment_index": 4 }, { "q": "Which changes are worth discussing", "a": "NHS patient materials describe possible sleepiness and dizziness; headache is also mentioned for pregabalin. This does not establish the cause of every complaint a reader has or an identical course for everyone. A troublesome effect, a change in daily life or weakening benefit deserves discussion even if someone continues to work successfully.\n\nReport separately if actual use differs from what was agreed, managing use has become difficult or the medicine is used for another purpose. You can describe a concrete episode and its consequences without diagnosing yourself. Obtaining it without a prescription or having an incomplete history does not make seeking help pointless; unknown information should be acknowledged honestly.\n\nAccounts of benefits and consequences complement each other. What became easier? What became harder? What difficulties appeared in relationships, work or safety? There is no need to increase use, stop the medicine or restart it for observation. A home experiment does not produce safe diagnostic proof.", "source_spans": [ { "role": "h2_heading", "start_utf16": 5816, "end_utf16": 5850, "sha256_utf8": "a491a2842bb95d9121d8ee2f278eebdafcba5bba4b262b843dfaf0637c3d07a2" }, { "role": "h2_answer", "start_utf16": 5852, "end_utf16": 6888, "sha256_utf8": "25453e515377bc766b8904a24882e81ce06e5d9c4fb8fdcbd0ea33458b78cefd" } ], "block_ids": [ "p0020", "p0021", "p0022" ], "source_segment_index": 5 }, { "q": "Combinations and professional review", "a": "In its warning of 19 December 2019, the FDA identifies breathing risks with gabapentin and pregabalin in people with certain risk factors: opioids and other central nervous system depressants, conditions that reduce lung function and older age. This is not a statement that every prescription carries an identical danger. Assessment depends on the particular situation.\n\nTell the doctor about other prescriptions, non-prescription medicines and substances, including alcohol. Professionally supervised treatment with several medicines does not automatically mean an error or addiction. It does require information about actual use; the absence of an unpleasant sensation does not establish safe compatibility. This article provides no combination table, timing or way to compensate for effects independently.\n\nFor a routine review, you can begin with the prescriber and ask whether the treatment goal still applies, how to assess current benefits and difficulties, who oversees the next plan and where to turn if things worsen. A pharmacist can help with questions about a particular medicine. A supportive conversation alone does not replace medical assessment of a potentially dangerous reaction or withdrawal. Do not stop abruptly, substitute the medicine or calculate changes independently; doubts can enter the conversation before you have a settled decision.", "source_spans": [ { "role": "h2_heading", "start_utf16": 6893, "end_utf16": 6929, "sha256_utf8": "340fb525cf372e0043723cac3e3a83461994987e85248137ee32e7dca2d7e329" }, { "role": "h2_answer", "start_utf16": 6931, "end_utf16": 8295, "sha256_utf8": "021815ee2c15e9946b6eb067bfe2beb78e2911d38dc3516c122dd2679a1b880c" } ], "block_ids": [ "p0024", "p0025", "p0026" ], "source_segment_index": 6 }, { "q": "Five optional fields for contacting help", "a": "These are original preparation prompts for a conversation, rather than a diagnostic questionnaire, risk scale or treatment. Use only what is already known. Any field may be left blank; notes are unnecessary during danger.\n\n1. **Medicine and purpose.** Its name, if known, why it was prescribed and what helped in your experience.\n2. **Actual history.** What has already happened with use, which changes were agreed and what remains unclear. Do not create a new change for observation.\n3. **Current difficulties.** Concerning sensations, changes in control or consequences, and when you noticed them, as far as you remember.\n4. **Other medicines and conditions.** Known prescriptions, supplements, substances and circumstances that matter to discuss with a doctor.\n5. **An accessible next contact.** Who can assess the situation, what makes seeking help difficult and what voluntary help from a relative is possible.\n\nYou can say it more briefly: “Treatment helped, but there are difficulties now; I want to understand this particular medicine.” There is no need to accept an addiction label beforehand, prove perfect motivation or obtain agreement from every relative.", "source_spans": [ { "role": "h2_heading", "start_utf16": 8300, "end_utf16": 8340, "sha256_utf8": "de4b2174ad40586dc7c42e02a1d173dd5ed77569bb9278c20f4b41c4d8e02304" }, { "role": "h2_answer", "start_utf16": 8342, "end_utf16": 9510, "sha256_utf8": "b1b00fad2331b9a5e01458d27af4aa337c89494777d89b3b5967d5d675ea9245" } ], "block_ids": [ "p0028", "p0029", "p0030" ], "source_segment_index": 7 }, { "q": "Help that takes real circumstances into account", "a": "Ask about language, cost, waiting time, contact format and an appropriate medical service. Ask where to turn if the proposed route is unsuitable and what to do if things worsen before the appointment. Confidentiality and information sharing should be clarified with the particular service; identical rights and free care in every country are not promised. [SAMHSA, setting up an appointment](https://www.samhsa.gov/find-support/health-care-or-support/how-to-set-up-an-appointment).\n\nWith an adult's consent, a relative can help with the known history, interpretation, transport or company. They should not choose treatment, secretly withhold medicine or become solely responsible for the outcome. Their own needs and manageable limits of involvement matter. [SAMHSA, caring for yourself while supporting someone](https://www.samhsa.gov/find-support/helping-someone/caring-for-yourself).\n\nChildren must not be assigned to monitor an adult's medicines or condition, or to rescue them. Where there are threats or violence, protecting the person harmed and children matters in its own right; involvement does not require enduring harm. Love, meaning and surroundings may support someone without replacing medical help or becoming conditions for access to it. After making contact, it matters to establish whether an actual assessment was received and who helps next; a booking or a new label does not by itself resolve the problem.", "source_spans": [ { "role": "h2_heading", "start_utf16": 9515, "end_utf16": 9562, "sha256_utf8": "58ea739cf20c8e8786c04d03229e673ba9ca8534531ec16711b3d9ca33075f7c" }, { "role": "h2_answer", "start_utf16": 9564, "end_utf16": 10991, "sha256_utf8": "2a1eb13e0c605c24aea1f3f730297b4fd68c0869f366f4bfbc63ffecc11ac1ee" } ], "block_ids": [ "p0032", "p0033", "p0034" ], "source_segment_index": 8 }, { "q": "Sources and limits", "a": "Selected sources checked on 14 October 2026. This article specifically examines gabapentin and pregabalin; other classes are mentioned to explain the limits of general labels. It does not establish a diagnosis, worldwide approval rules or access to care, and offers no regimen for changing treatment independently.\n\n- [NHS, About gabapentin](https://www.nhs.uk/medicines/gabapentin/about-gabapentin/) — reviewed 19 February 2026; the main text on use and risks was personally read. Numerical prescriptions, brand switching and UK entitlements were not imported.\n- [NHS, About pregabalin](https://www.nhs.uk/medicines/pregabalin/about-pregabalin/) — reviewed 20 January 2026; the main text was personally read, including the warning about missed doses in epilepsy. Not a check of all prescribing information or an individual prescription.\n- [FDA, Gabapentin/Pregabalin: Serious Breathing Problems](https://www.fda.gov/safety/medical-product-safety-information/neurontin-gralise-horizant-gabapentin-and-lyrica-lyrica-cr-pregabalin-drug-safety-communication) — 19 December 2019; the standalone official communication about breathing risks and risk factors was personally read. Full studies, current labels and numerical individual risk were not assessed.\n- [MHRA, Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs](https://www.gov.uk/drug-safety-update/improving-information-supplied-with-gabapentinoids-pregabalin-slash-gabapentin-benzodiazepines-and-z-drugs) — 8 January 2026; the author's verified reading of the communication on risks and information, within its review scope. Not a universal stopping protocol.\n- [NHS, Poisoning](https://www.nhs.uk/conditions/poisoning/) — reviewed 12 June 2025; the author's verified reading on urgent help for suspected dangerous poisoning, rather than home procedures.\n- [NIMH, Depression](https://www.nimh.nih.gov/health/publications/depression) — revised 2024; the author's verified reading on help during immediate danger, rather than a diagnosis of the reader.\n- [SAMHSA, How to Set Up an Appointment](https://www.samhsa.gov/find-support/health-care-or-support/how-to-set-up-an-appointment) — 24 April 2023; the author's reading of official substantive content on contact and access, rather than a guarantee of a local appointment.\n- [SAMHSA, Caring for Yourself](https://www.samhsa.gov/find-support/helping-someone/caring-for-yourself) — 24 April 2023; the author's reading of official substantive content on manageable boundaries and personal support, rather than evidence of the effectiveness of family treatment.", "source_spans": [ { "role": "h2_heading", "start_utf16": 10996, "end_utf16": 11014, "sha256_utf8": "f91f16500d95114ea5dd62762b302ab95f247ca4f49fe0affb04993b09f0a299" }, { "role": "h2_answer", "start_utf16": 11016, "end_utf16": 13629, "sha256_utf8": "1e33868be8f11f8e98c38fe770129346f3507d6b070d8a1d75faa5bbed7b0062" } ], "block_ids": [ "p0036", "p0037" ], "source_segment_index": 9 }, { "q": "Tags", "a": "gabapentinoids; gabapentin; pregabalin; beneficial treatment; nerve pain; epilepsy; physical dependence; control over use; withdrawal; breathing risks; prescription review; relatives' boundaries", "source_spans": [ { "role": "h2_heading", "start_utf16": 13634, "end_utf16": 13638, "sha256_utf8": "1331275bc537b4c2bf1e46f7275677967515342e30b572e6852fa6f51b831fe8" }, { "role": "h2_answer", "start_utf16": 13640, "end_utf16": 13834, "sha256_utf8": "53c124c295988fa9f7acf4cac14b61603fb192b10ffe283d1fd53019c2e86178" } ], "block_ids": [ "p0039" ], "source_segment_index": 10 }, { "q": "About the authors", "a": "Andrey Zarinsh is the author and founder of United Wisdom. He explores inner transformation, the unity of traditions, intercultural dialogue and contemporary spiritual discipline. Instagram: @andrey.zarinsh.\n\nMaria Evilkut is a co-author of United Wisdom. Alongside her research, she seeks to test these ideas in practice and observe how principles of unity and mutual understanding work in real life between people and cultures. Instagram: @ilkutki.", "source_spans": [ { "role": "h2_heading", "start_utf16": 13839, "end_utf16": 13856, "sha256_utf8": "e120452a2b9952200310f55df00e52d0bbd068d32bba8a322511ed65e3d4967d" }, { "role": "h2_answer", "start_utf16": 13858, "end_utf16": 14308, "sha256_utf8": "b807861bc19a25ab91f45e5acc6d733c04ea03b84b346d9e77c2381c9e3498ed" } ], "block_ids": [ "p0041", "p0042" ], "source_segment_index": 11 } ], "claims": [], "claims_policy": "no_reclassified_claims", "sources": [ { "id": "src_e0b85f92f8b0507b", "title": "FDA, Gabapentin/Pregabalin: Serious Breathing Problems", "url": "https://www.fda.gov/safety/medical-product-safety-information/neurontin-gralise-horizant-gabapentin-and-lyrica-lyrica-cr-pregabalin-drug-safety-communication", "source_spans": [ { "role": "markdown_link", "start_utf16": 993, "end_utf16": 1174, "sha256_utf8": "9c640d845b4e5e5c4f5699392df036e952c70f1760dc2338b2a88e5f9125b280" }, { "role": "markdown_link", "start_utf16": 11856, "end_utf16": 12071, "sha256_utf8": "e75d2d3705046943e809a265f38fcc590cd882ff59dbddda20bcb899614cabc1" } ], "read_scope": "- [FDA, Gabapentin/Pregabalin: Serious Breathing Problems](https://www.fda.gov/safety/medical-product-safety-information/neurontin-gralise-horizant-gabapentin-and-lyrica-lyrica-cr-pregabalin-drug-safety-communication) — 19 December 2019; the standalone official communication about breathing risks and risk factors was personally read. Full studies, current labels and numerical individual risk were not assessed.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 11854, "end_utf16": 12267, "sha256_utf8": "f2202f634e3da57cca3c5d92a1da0f1a6dcf492a66ef72ea509fcae078a56722" }, "shared_entry_urls": [] }, { "id": "src_10790fb1fab48f9a", "title": "NHS, Poisoning", "url": "https://www.nhs.uk/conditions/poisoning/", "source_spans": [ { "role": "markdown_link", "start_utf16": 1455, "end_utf16": 1513, "sha256_utf8": "4df8a92091531b6a767c67412d798b2ba441449a7c75ce3f1df2da2181151083" }, { "role": "markdown_link", "start_utf16": 12685, "end_utf16": 12743, "sha256_utf8": "c856a80773ac625d62d1ae76d38ae84591b6453e27268e52b90c33b8d6c136bc" } ], "read_scope": "- [NHS, Poisoning](https://www.nhs.uk/conditions/poisoning/) — reviewed 12 June 2025; the author's verified reading on urgent help for suspected dangerous poisoning, rather than home procedures.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 12683, "end_utf16": 12877, "sha256_utf8": "998c60b65d119229f3bf5b14a02149234a11029558567db42f23ba31d9319d63" }, "shared_entry_urls": [] }, { "id": "src_a16ec569ffdc8d21", "title": "NIMH, Depression", "url": "https://www.nimh.nih.gov/health/publications/depression", "source_spans": [ { "role": "markdown_link", "start_utf16": 1771, "end_utf16": 1846, "sha256_utf8": "02979853d19dbe3a0c7ed66ffb4a337e35df7d7a6b30984a310ef4deeca9d7cf" }, { "role": "markdown_link", "start_utf16": 12880, "end_utf16": 12955, "sha256_utf8": "02979853d19dbe3a0c7ed66ffb4a337e35df7d7a6b30984a310ef4deeca9d7cf" } ], "read_scope": "- [NIMH, Depression](https://www.nimh.nih.gov/health/publications/depression) — revised 2024; the author's verified reading on help during immediate danger, rather than a diagnosis of the reader.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 12878, "end_utf16": 13073, "sha256_utf8": "450aa31a800d4a3313ba44e1b365820913ea3e3fcc1920049700e30abb5f4475" }, "shared_entry_urls": [] }, { "id": "src_561e3d8a294d44cb", "title": "NHS, About gabapentin", "url": "https://www.nhs.uk/medicines/gabapentin/about-gabapentin/", "source_spans": [ { "role": "markdown_link", "start_utf16": 2291, "end_utf16": 2367, "sha256_utf8": "ec3a17943438ac5569de0b1f9e8bd0c5ef5152223345eec9784c878050dfec40" }, { "role": "markdown_link", "start_utf16": 11334, "end_utf16": 11416, "sha256_utf8": "9c2d5255e9702c4fb2d7e4a10f1c1bc4f8c7cb1c2002762e258a1af82c7d14c7" } ], "read_scope": "- [NHS, About gabapentin](https://www.nhs.uk/medicines/gabapentin/about-gabapentin/) — reviewed 19 February 2026; the main text on use and risks was personally read. Numerical prescriptions, brand switching and UK entitlements were not imported.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 11332, "end_utf16": 11577, "sha256_utf8": "881888012f593339cb68341b20b44857b61cccc8f0b225588b84e425d9412879" }, "shared_entry_urls": [] }, { "id": "src_11661f4242adab30", "title": "NHS, About pregabalin", "url": "https://www.nhs.uk/medicines/pregabalin/about-pregabalin/", "source_spans": [ { "role": "markdown_link", "start_utf16": 2369, "end_utf16": 2445, "sha256_utf8": "83b9b74db1a2553a9a8f7627ff89252c060dd78f051c59615f4c4c5360483b76" }, { "role": "markdown_link", "start_utf16": 11580, "end_utf16": 11662, "sha256_utf8": "4322f8fee8261bdb96292ef022c94f0e1a451cb199d224d108cfc0b4851e575b" } ], "read_scope": "- [NHS, About pregabalin](https://www.nhs.uk/medicines/pregabalin/about-pregabalin/) — reviewed 20 January 2026; the main text was personally read, including the warning about missed doses in epilepsy. Not a check of all prescribing information or an individual prescription.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 11578, "end_utf16": 11853, "sha256_utf8": "f1e5d934dfed115ba6f43c6fe45185d63df2af49f3896d2d48ad261227f8c027" }, "shared_entry_urls": [] }, { "id": "src_0e3b8b7f299456c3", "title": "MHRA, Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs", "url": "https://www.gov.uk/drug-safety-update/improving-information-supplied-with-gabapentinoids-pregabalin-slash-gabapentin-benzodiazepines-and-z-drugs", "source_spans": [ { "role": "markdown_link", "start_utf16": 3565, "end_utf16": 3742, "sha256_utf8": "7a6c74cccb90379c14f9b4865113da27c6d979b9ddbf41951c951b9899edcb55" }, { "role": "markdown_link", "start_utf16": 12270, "end_utf16": 12527, "sha256_utf8": "72b8483ab0f432faed7a913d1b9f4c9634f40ed3251007bc0fd95f25de8bcd85" } ], "read_scope": "- [MHRA, Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs](https://www.gov.uk/drug-safety-update/improving-information-supplied-with-gabapentinoids-pregabalin-slash-gabapentin-benzodiazepines-and-z-drugs) — 8 January 2026; the author's verified reading of the communication on risks and information, within its review scope. Not a universal stopping protocol.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 12268, "end_utf16": 12682, "sha256_utf8": "076ecf9f02d853c5dd8549f5691943814c9fa546789dc40e13700675eb79eea6" }, "shared_entry_urls": [] }, { "id": "src_96d8458a638ca14b", "title": "SAMHSA, How to Set Up an Appointment", "url": "https://www.samhsa.gov/find-support/health-care-or-support/how-to-set-up-an-appointment", "source_spans": [ { "role": "markdown_link", "start_utf16": 9920, "end_utf16": 10044, "sha256_utf8": "1c12e4f2d5bda4c3ccdd0105198c64e8e50e4b9091c74d16c28c37e3c2fea18a" }, { "role": "markdown_link", "start_utf16": 13076, "end_utf16": 13203, "sha256_utf8": "a74ebfa3d6bfe41b7bace4eec82e3ba2ccfbe77fda2a776c325b82072a93768e" } ], "read_scope": "- [SAMHSA, How to Set Up an Appointment](https://www.samhsa.gov/find-support/health-care-or-support/how-to-set-up-an-appointment) — 24 April 2023; the author's reading of official substantive content on contact and access, rather than a guarantee of a local appointment.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 13074, "end_utf16": 13344, "sha256_utf8": "17cff9f1ded2365462d5a06e0aa4510bf12b68839ee4f2e34aedd2399d2daf04" }, "shared_entry_urls": [] }, { "id": "src_c7cfed956c8066f2", "title": "SAMHSA, Caring for Yourself", "url": "https://www.samhsa.gov/find-support/helping-someone/caring-for-yourself", "source_spans": [ { "role": "markdown_link", "start_utf16": 10322, "end_utf16": 10449, "sha256_utf8": "44104394bc28e2b7e7aa3d384513437fd8d91c4c32f74c57393a36be19293f1c" }, { "role": "markdown_link", "start_utf16": 13347, "end_utf16": 13449, "sha256_utf8": "db10acdcd5a327dfe4ba5b13bc5b038262a0f310b7707317de38fa309598ad51" } ], "read_scope": "- [SAMHSA, Caring for Yourself](https://www.samhsa.gov/find-support/helping-someone/caring-for-yourself) — 24 April 2023; the author's reading of official substantive content on manageable boundaries and personal support, rather than evidence of the effectiveness of family treatment.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 13345, "end_utf16": 13629, "sha256_utf8": "18e80dc7697472553b4698d4b1e345c9a8716432b7f5f94fa38e75c94c1c1681" }, "shared_entry_urls": [] } ], "retrieval_limits": [ "This local GEO representation applies only to the specified source article version and its SHA-256.", "Qualifications, sources and attributions remain in the full sections and byte-identical Markdown copy.", "No new source research was conducted in this GEO stage." ], "master_sha256": "f6f1b8d3705d6f00772784d0dbe3040e3214176022b8d8f5a68af1f184c14802", "provenance": { "raw_reader_sha256": "f6f1b8d3705d6f00772784d0dbe3040e3214176022b8d8f5a68af1f184c14802", "ru_master_sha256": "aa9b56e964ecb821c248ff4e85114cfedd79b39163fd49a69e1b7f3fcf2beb63", "reader_path": "outputs/uw-addictions-corpus-20261013/articles/DEP-06-N08/ARTICLE_EN.md", "review_pointer": "outputs/uw-addictions-corpus-20261013/articles/DEP-06-N08/INDEPENDENT_REVIEW.json", "review_sha256": "3c846227fcd69b3cecf214ac7407725f82647cb096b4a5ee9822d3ce0f5fd0cc", "clean_md_relative_filename": "GEO.en.md", "body_length_utf16": 14309, "source_segments": [ { "kind": "opening", "index": 0, "heading": null, "start_utf16": 0, "end_utf16": 585, "sha256_utf8_raw_slice": "c7f59d1d7ef793d295c75de6509046746565a3e7ad378c9894bee9e4ee1df99e" }, { "kind": "h2_section", "index": 1, "heading": "A dangerous state matters more than an exact label", "start_utf16": 585, "end_utf16": 1849, "sha256_utf8_raw_slice": "ff338306893f1c20957195b2c4e33222845575b7d0fe735d7c212b062ac2b2ab" }, { "kind": "h2_section", "index": 2, "heading": "Consider the particular medicine and its purpose", "start_utf16": 1849, "end_utf16": 3134, "sha256_utf8_raw_slice": "f2a39cc653ebe3712bfa3d8fce9d94559466f8ce52d50b7eacadb8eafd70a06b" }, { "kind": "h2_section", "index": 3, "heading": "Adaptation, withdrawal and difficulties with control", "start_utf16": 3134, "end_utf16": 4574, "sha256_utf8_raw_slice": "4cca10adde4d82e3652e066e6558dbf8392307275c882068887c57ec34c99a05" }, { "kind": "h2_section", "index": 4, "heading": "Why every medicine cannot be grouped together", "start_utf16": 4574, "end_utf16": 5813, "sha256_utf8_raw_slice": "bf2e6617d698e39bac9212e4d0d5b62f63aaf81432fe886212ea9d381167bea4" }, { "kind": "h2_section", "index": 5, "heading": "Which changes are worth discussing", "start_utf16": 5813, "end_utf16": 6890, "sha256_utf8_raw_slice": "97c31b55f300b2f14c68c2412e1e425634e54d6af1b298d3c9953ee5256474f3" }, { "kind": "h2_section", "index": 6, "heading": "Combinations and professional review", "start_utf16": 6890, "end_utf16": 8297, "sha256_utf8_raw_slice": "a24c5195efe2304da9d49fd5f1610d63daee8f70fe6cb6118f0c9efe26def8ab" }, { "kind": "h2_section", "index": 7, "heading": "Five optional fields for contacting help", "start_utf16": 8297, "end_utf16": 9512, "sha256_utf8_raw_slice": "8796922f7adec90c67527913b3fa183dcf4e4960604574ca5df89c18f9d1fc2c" }, { "kind": "h2_section", "index": 8, "heading": "Help that takes real circumstances into account", "start_utf16": 9512, "end_utf16": 10993, "sha256_utf8_raw_slice": "2104323c92dd54371d4b1e3787df87cb64448276fb74713f236abad923d4c869" }, { "kind": "h2_section", "index": 9, "heading": "Sources and limits", "start_utf16": 10993, "end_utf16": 13631, "sha256_utf8_raw_slice": "f028329d1236d809b54f1353a538a45b361d64292c88e76bcdc1390ad856ec1f" }, { "kind": "h2_section", "index": 10, "heading": "Tags", "start_utf16": 13631, "end_utf16": 13836, "sha256_utf8_raw_slice": "fd74c5ccf9f13d3e63feb4acdc48e186449ea018511308da046fad976ed1f111" }, { "kind": "h2_section", "index": 11, "heading": "About the authors", "start_utf16": 13836, "end_utf16": 14309, "sha256_utf8_raw_slice": "d6b6d738ad7ec362dacb20b9eef0ecc9afe89201c6bdbfa109116cff85ded416" } ], "common_blocks_module_sha256": "6cf638661a819f960c39d08058bf6d0d0696e8b816f677d95b389f5f1d11e4d2" } }